What you should be spending your R&D budget on next year
23rd August 2019

R&D tax credits are vital to any innovative company – they enable you to continue funding the development of your product, service or solution. When it comes to calculating how much cash you’ll receive back, it will depend on whether you’re eligible under the SME R&D tax credit scheme or large company Research and Development Expenditure Credit (RDEC). How much you receive back will also depend on how much you’ve spent on eligible expenditure such as for materials or software. For more detailed information on calculating your R&D tax credit we recommend reading “What costs can I recover through R&D?”.

During the 2018 Autumn Budget, it was announced that a new proposal would reintroduce a cap on R&D tax credits in order to tackle fraudulent claims where companies have been set up in the UK but little or no activity takes place in the country. The original cap that was put in place limited the maximum you could claim back in tax credits to the equivalent amount of the company’s qualifying PAYE and NIC costs but this rule was scrapped in April 2012.

The new cap which is due to start in April 2020 only affects loss-making companies who are claiming through the SME R&D tax credit scheme (not the RDEC scheme). It is slightly more generous than the original cap in that it will allow the maximum to be claimed to be three times the amount of a company’s qualifying PAYE and NIC liability. Despite the leniency compared to the 2012 rule, it is predicted to particularly hit hard at start-ups and smaller companies who may be more reliant on contractors to carry out their R&D work. It will also affect those companies who outsource their clinical trials to hospitals and universities which is common practice for many in the Biotech sector.

The proposal is still in consultation and considerations are being made towards genuine smaller R&D companies. Possible initiatives to alleviate the burden include granting a de minimis threshold which would allow companies to claim more than their PAYE and NIC cap so long as it falls below the threshold. Other possibilities to make the cap fairer include allowing a company to carry forward the losses that have been blocked by the cap in future years.

In practice what this really means is that you should carry on calculating your R&D claim as per the normal calculations. Where the amount due back to you is more than what you need to pay in three times your PAYE and NIC you will not be able to claim the remaining difference. This will only apply to you if your company is expecting to make a loss. Our advice is that when planning your budget for next year, where possible, you allocate more to hiring in-house in order to allow yourself a larger R&D tax credit claim. If you’d like any further advice or would like to discuss please give us a call to set up a free consultation on 01865 245511.

About the author

Ridgefield Consulting
Kizzy is responsible for the content creation of informative resources on the Ridgefield Consulting website.

Latest news

Research, industry, and AGI

Research, industry, and AGI

A transfer of knowledge to industry is a good thing:  One purpose of a university is to benefit society by disseminating knowledge, and one way this can be done is by commercialising research. Universities and research institutions are a dynamo for entrepreneurship, and for innovation in large companies. READ MORE

For success in product development – start at square zero

For success in product development – start at square zero

When it comes to the commercial success of a technology-led product, there are a number of factors that come into play along the development journey. Have the regulatory requirements been met? Can the design be produced at a viable cost? Is it possible to ensure the quality of the manufacturing process? The list goes on. READ MORE

The not-so-small matter of scale: Making it big in microfluidics

The not-so-small matter of scale: Making it big in microfluidics

Microfluidics is a key technology enabling the development of rapid in-vitro diagnostics (IVD). With applications including COVID-19 testing, cardiac arrest assessment and STD screening, decentralised rapid diagnostics are shaping up to be a major part of the future of healthcare and wellness monitoring. READ MORE



Visit Britain

Keep in touch

Sign up to the Venturefest Oxford newsletter to make sure you are the first to hear the latest news. The next #vfestox newsletter will be coming out soon! Make sure you're on the list!






Email Preferences

Make connections that lead to new investments, new businesses and new ideas in the high-tech sector in Oxfordshire.